UNLABELLED: Multivariate logistic regression analysis showed that serum IGF-I level was significantly lower in postmenopausal diabetic women with vertebral fractures than in those without fractures. Serum IGF-I level could be clinically useful for assessing the risk of vertebral fractures independent of BMD in postmenopausal women with type 2 diabetes. INTRODUCTION: We investigated the relationships among serum IGF-I and C-peptide levels, BMD, and vertebral fractures in postmenopausal women with type 2 diabetes. METHODS: A total of 131 postmenopausal women with type 2 diabetes were consecutively recruited, and radiographic and biochemical characteristics were collected. RESULTS: Either IGF-I or C-peptide was not correlated with BMD at any site or bone metabolic markers, such as osteocalcin (OC) and urinary N-terminal cross-linked telopeptide of type-I collagen (uNTX). However, serum IGF-I level was significantly lower in subjects with vertebral fractures than in those without fractures (mean +/- SD: 106.9 +/- 50.0 vs. 142.8 +/- 50.8 ng/ml, p = 0.0006). When multivariate logistic regression analysis was performed with the presence of vertebral fractures as a dependent variable and serum IGF-I adjusted for the parameters described above as independent variables, IGF-I was selected as an index affecting the presence of vertebral fractures [odds ratio = 0.436, 95% confidential interval 0.234-0.814 per SD increase, p = 0.0092]. This significance was almost the same after additional adjustment for lumbar BMD or C-peptide. CONCLUSIONS: Serum IGF-I level could be clinically useful for assessing the risk of vertebral fractures independent of BMD in postmenopausal women with type 2 diabetes.
UNLABELLED: Multivariate logistic regression analysis showed that serum IGF-I level was significantly lower in postmenopausal diabeticwomen with vertebral fractures than in those without fractures. Serum IGF-I level could be clinically useful for assessing the risk of vertebral fractures independent of BMD in postmenopausal women with type 2 diabetes. INTRODUCTION: We investigated the relationships among serum IGF-I and C-peptide levels, BMD, and vertebral fractures in postmenopausal women with type 2 diabetes. METHODS: A total of 131 postmenopausal women with type 2 diabetes were consecutively recruited, and radiographic and biochemical characteristics were collected. RESULTS: Either IGF-I or C-peptide was not correlated with BMD at any site or bone metabolic markers, such as osteocalcin (OC) and urinary N-terminal cross-linked telopeptide of type-I collagen (uNTX). However, serum IGF-I level was significantly lower in subjects with vertebral fractures than in those without fractures (mean +/- SD: 106.9 +/- 50.0 vs. 142.8 +/- 50.8 ng/ml, p = 0.0006). When multivariate logistic regression analysis was performed with the presence of vertebral fractures as a dependent variable and serum IGF-I adjusted for the parameters described above as independent variables, IGF-I was selected as an index affecting the presence of vertebral fractures [odds ratio = 0.436, 95% confidential interval 0.234-0.814 per SD increase, p = 0.0092]. This significance was almost the same after additional adjustment for lumbar BMD or C-peptide. CONCLUSIONS: Serum IGF-I level could be clinically useful for assessing the risk of vertebral fractures independent of BMD in postmenopausal women with type 2 diabetes.
Authors: H Hanaire-Broutin; B Sallerin-Caute; M F Poncet; M Tauber; R Bastide; R Rosenfeld; J P Tauber Journal: Diabetes Metab Date: 1996-07 Impact factor: 6.041
Authors: G C Isaia; P Ardissone; M Di Stefano; D Ferrari; V Martina; M Porta; M Tagliabue; G M Molinatti Journal: Acta Diabetol Date: 1999-06 Impact factor: 4.280
Authors: U A Liberman; S R Weiss; J Bröll; H W Minne; H Quan; N H Bell; J Rodriguez-Portales; R W Downs; J Dequeker; M Favus Journal: N Engl J Med Date: 1995-11-30 Impact factor: 91.245
Authors: Michael F Holick; Joseph J Lamb; Robert H Lerman; Veera R Konda; Gary Darland; Deanna M Minich; Anuradha Desai; Tai C Chen; Melissa Austin; Jacob Kornberg; Jyh-Lurn Chang; Alex Hsi; Jeffrey S Bland; Matthew L Tripp Journal: J Bone Miner Metab Date: 2009-12-19 Impact factor: 2.626
Authors: P K Fazeli; A T Faje; E Meenaghan; S T Russell; M Resulaj; H Lee; C J Rosen; M L Bouxsein; A Klibanski Journal: Osteoporos Int Date: 2019-10-28 Impact factor: 4.507